News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
134 Results
Type
Article (5)
Company Profile (1)
Press Release (128)
Section
Business (36)
Drug Development (12)
FDA (4)
Job Trends (1)
News (50)
Policy (6)
Tag
Alliances (2)
Approvals (2)
Best Places to Work (1)
Cancer (1)
Clinical research (16)
COVID-19 (38)
C-suite (3)
Data (15)
Earnings (27)
Events (21)
FDA (10)
Gene editing (1)
Gene therapy (1)
GLP-1 (1)
Healthcare (1)
Immunology and inflammation (1)
Infectious disease (39)
IPO (1)
Lymphoma (1)
People (24)
Phase 1 (6)
Phase 2 (3)
Phase 3 (9)
Pipeline (11)
Regulatory (12)
RSV (1)
Vaccines (6)
Date
Last 7 days (2)
Last 30 days (4)
Last 365 days (44)
2026 (5)
2025 (44)
2024 (41)
2023 (33)
2022 (11)
Location
Australia (1)
Connecticut (15)
Europe (1)
Massachusetts (53)
New Hampshire (2)
United States (70)
134 Results for "invivyd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
January 8, 2026
·
18 min read
Press Releases
Invivyd Announces Proposed Public Offering of Common Stock
November 18, 2025
·
4 min read
Press Releases
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
November 26, 2025
·
1 min read
Press Releases
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
December 24, 2025
·
7 min read
Press Releases
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
February 3, 2026
·
9 min read
Press Releases
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
January 20, 2026
·
13 min read
Press Releases
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
November 18, 2025
·
5 min read
Press Releases
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 6, 2025
·
19 min read
Press Releases
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
December 24, 2025
·
9 min read
Press Releases
Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025
November 3, 2025
·
1 min read
1 of 14
Next
